Grace M Callagy

Summary

Affiliation: National University of Ireland
Country: Ireland

Publications

  1. ncbi Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
    Grace M Callagy
    Department of Pathology, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland
    BMC Cancer 8:153. 2008
  2. ncbi Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
  3. ncbi A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene
    Huai En Huang
    Cancer Genomics Program, Hutchison MRC Research Centre, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Cancer Res 64:6840-4. 2004

Collaborators

  • Joseph Ragaz
  • D Birnbaum
  • William John Gullick
  • P D Pharoah
  • Huai En Huang
  • José Adélaïde
  • Jocelyne Jacquemier
  • Valerie Jeanne Bardou
  • Jessica C Pole
  • Suet Feung Chin
  • Max Chaffanet
  • Maria J Garcia
  • Christophe Ginestier
  • Stephen M Hewitt
  • N Gopalakrishna Iyer
  • Carlos Caldas
  • Paul A W Edwards
  • Huai-En Huang
  • Suet-Feung Chin

Detail Information

Publications3

  1. ncbi Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
    Grace M Callagy
    Department of Pathology, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland
    BMC Cancer 8:153. 2008
    ..Here, we present the results of a meta-analysis of the association between BCL2 expression and both disease free survival (DFS) and overall survival (OS) in female breast cancer...
  2. ncbi Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
    ..We validated the results in an independent series. Experimental Design and..
  3. ncbi A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene
    Huai En Huang
    Cancer Genomics Program, Hutchison MRC Research Centre, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Cancer Res 64:6840-4. 2004
    ..They were, like breast tumors in general, mainly ErbB2 low (11 of 13 were low) and estrogen receptor positive (11 of 13 positive)...